LQDA
Liquidia Corporation · Healthcare · Medical - Pharmaceuticals
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | +1 | 10 | $303 | +1 | n/a |
| Q2 2026 | 100 | +24 | 36.67M | $2.92B | +27 | −3 |
| Q1 2026 | 79 | -1 | 26.51M | $999.68M | +6 | −8 |
| Q4 2025 | 81 | 0 | 26.44M | $911.45M | +1 | n/a |
| Q3 2025 | 17 | +1 | 21.94M | $498.92M | +1 | n/a |
| Q2 2025 | 13 | -2 | 14.83M | $184.82M | n/a | −2 |
| Q1 2025 | 12 | 0 | 5.71M | $84.24M | n/a | n/a |
| Q4 2024 | 12 | +4 | 4.81M | $56.51M | +4 | n/a |
| Q3 2024 | 7 | -2 | 2.07M | $20.68M | +1 | −3 |
| Q2 2024 | 9 | n/a | 2.26M | $27.08M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assetmark, Inc | 10 | New | $303 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Assetmark, Inc | $303 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 242 holders, 61.34M shares, $2.26B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 7.30K sh · $207,932
Officer · 13.69K sh · $389,948
Officer · 9.22K sh · $262,529
Officer · 8.86K sh · $252,418
Officer · 5.25K sh · $149,378
Officer · 1.10K sh · $31,356
Officer · 18.94K sh · $539,354
Officer, Director · 32.74K sh · $932,549
Officer · 5.89K sh · $167,804
Director · 235.48K sh · $6.39M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology